menu
    • menu
    [{"orgOrder":0,"company":"280Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TEB-17231","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"280Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"280Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"280Bio \/ Undisclosed"},{"orgOrder":0,"company":"280Bio","sponsor":"280Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I","graph3":"280Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"280Bio \/ 280Bio","highestDevelopmentStatusID":"6","companyTruncated":"280Bio \/ 280Bio"},{"orgOrder":0,"company":"280Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"YL-17231","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"280Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"280Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"280Bio \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by 280Bio

    Menu

    280Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            280Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            280Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic ...

                            Details : Gemcitabine is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 10, 2024

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            280Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            280Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YL-17231

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            280 Bio Receives IND Approval from the FDA for YL-17231

                            Details : YL-17231 has a broader activity than many current KRAS inhibitors and demonstrated strong inhibition of in vivo KRAS mutant xenograft tumor growth in our preclinical investigations.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 07, 2023

                            Lead Product(s) : YL-17231

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            280Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            280Bio

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TEB-17231

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            280Bio Provides Update on the KRAS Inhibitor TEB-17231 at the 2023 AACR Annual Meeting

                            Details : TEB-17231 is a KRAS Inhibitor, it has shown robust tumor growth inhibition, against KRASG12V, KRASG12C, KRASG12D and other RAS mutant tumor cell lines. It is in preparation for phase1 studies for the treatment of KRAS-mutated cancer patients.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 21, 2023

                            Lead Product(s) : TEB-17231

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth